J&J rounds out the year with twin buyouts, gaining control of delivery and surgical robotics tech
J&J is scooping up one of Bristol-Myers-Squibb’s biotech partners specialized in bladder biology, with a particularly keen interest in a technology that releases cancer drugs locally.
The pharma giant isn’t looking to make a splash here — the financial terms remain undisclosed — but they are clear that they see a potential for Taris’ silicone-based drug delivery device far beyond bladder cancer.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 87,700+ biopharma pros reading Endpoints daily — and it's free.